Recent developments in Type 2 diabetes treatment highlight the significant impact of combining GLP-1 therapies with continuous glucose monitors (CGMs). A new study from IQVIA MedTech indicates that patients utilizing both methods experienced quicker and more substantial improvements in glycemic control compared to those on GLP-1 therapy alone. This research, based on one of the largest healthcare datasets involving over 13,000 patients, provides crucial insights for industry stakeholders on the benefits of integrated treatment approaches, particularly in accelerating HbA1c improvements. The findings underscore the potential of real-world data to enhance market access and commercial strategies in the diabetes care sector.
Disclaimer: This summary is written by AI, which can make mistakes. Please follow up on any news information from additional sources.
Link to original article source: https://www.iqvia.com/sub-brands/medtech/library/white-papers/iqvia-medtech-data-informs-type-2-diabetes-therapy
